Plan for the worst so you're best prepared.

Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 18% on Tuesday after the company published preclinical data showing its lead candidate TTX-MC138 demonstrated therapeutic potential ...

TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive ...

Glioblastoma is the most aggressive primary brain cancer, with median survival under two years from diagnosis despite current standard-of-care interventions. The molecular target of TTX-MC138, ...

TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...

BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's ...

Contributing Editor Jan Ozer recently spoke with Alex Davies, senior analyst at Rethink Technology Research, about Rethink’s new report, “The Media and Entertainment Transcoding Workload and Device ...

In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...

It looks to me that apple audio products like AirPods handle audio transmission better than the standard Bluetooth audio. It will send the actual aac file to the audio device to be decoded on the ...

What happens when a trusted tech brand makes a decision that fundamentally alters how its products are used? For Synology, the answer is unfolding in real-time, as its recent move to eliminate ...